Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2022-11-14 |
2022-09 |
0 |
N/A |
N/A |
N/A |
2022-08-04 |
2022-06 |
-1.13 |
N/A |
N/A |
N/A |
2022-05-12 |
2022-03 |
-1.02 |
N/A |
N/A |
N/A |
2022-03-24 |
2021-12 |
-1 |
N/A |
N/A |
N/A |
2021-11-15 |
2021-09 |
-1.13 |
N/A |
N/A |
N/A |
2021-08-12 |
2021-06 |
-0.84 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2021-06-04 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2021-04-01 |
Jefferies |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2021-01-31 |
COLES N. ANTHONY |
Officer and Director |
743.68K |
Stock Award(Grant) |
2022-12-01 |
EPSTEIN MARIE N. |
Officer |
8.88K |
Sale |
2021-01-31 |
HEYMAN RICHARD A |
Director |
8.12K |
Stock Award(Grant) |
2021-01-31 |
KELLY JEFFERY W. |
Director |
13.24K |
Stock Award(Grant) |
2022-02-02 |
MOHSEN PAULASH |
Officer |
59.14K |
Sale |
2022-12-01 |
PETERS RICHARD |
Chief Executive Officer |
90.03K |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2022-09-29 |
FMR, LLC |
1.63M |
3.08M |
15.00% |
2022-09-29 |
Vanguard Group, Inc. (The) |
262.34K |
495.83K |
2.42% |
2022-09-29 |
Artal Group S.A. |
217.39K |
410.87K |
2.00% |
2022-09-29 |
Renaissance Technologies, LLC |
68.72K |
129.88K |
0.63% |
2022-09-29 |
Geode Capital Management, LLC |
55.53K |
104.96K |
0.51% |
2022-09-29 |
Citadel Advisors Llc |
49.54K |
93.64K |
0.46% |
Report Date |
Organization |
Position |
Value |
Percentage |
2022-10-30 |
Fidelity Growth Company Fund |
509.00K |
962.01K |
4.69% |
2022-10-30 |
Fidelity Select Portfolios - Biotechnology |
260.18K |
491.74K |
2.40% |
2022-09-29 |
Vanguard Total Stock Market Index Fund |
230.84K |
436.28K |
2.13% |
2022-10-30 |
Fidelity Growth Company K6 Fund |
133.37K |
252.07K |
1.23% |
2022-10-30 |
Fidelity Series Growth Company Fund |
82.39K |
155.72K |
0.76% |
2022-09-29 |
Vanguard Extended Market Index Fund |
29.19K |
55.17K |
0.27% |
Split |
Date |
1 : 7 |
2022-12-19 |
1 : 20 |
2020-12-23 |